HealthDay on MSN
FDA approves Icotyde for moderate-to-severe plaque psoriasis
The U.S. Food and Drug Administration has approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for ...
Shannon, now 26, from Manchester, was diagnosed with psoriasis - an autoimmune condition affecting more than a million ...
Mount Sinai researchers have published the first organ-wide human skin spatial atlas from across the body. It provides an ...
Sonny Hook is undergoing chemotherapy and steroid treatment after being diagnosed with Langerhans cell histiocytosis (LCH) ...
Scientists have identified the transporter protein that allows essential fats in the bloodstream to enter the skin, reshaping ...
FDA approves icotrokinra, an oral interleukin-23 receptor antagonist, for adults and pediatric patients with moderate to ...
"I was very ashamed. I felt like everywhere people were judging me," Amber Dean tells PEOPLE, recalling when her symptoms ...
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s oral psoriasis drug, Icotyde. THE DETAILS The once ...
"Walking around with this very visible, very robust ailment has a pretty tremendous impact on your mental health," Maddox ...
Alumis said its drug, envudeucitinib, met all primary and secondary endpoints in two Phase 3 trials in patients with moderate-to-severe plaque psoriasis. About 65% of patients achieved near-complete ...
Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety ...
Metronidazole-Based Standard of Care with Favorable Tolerability MIAMI BEACH, Fla., March 19, 2026 /PRNewswire/ -- Crescel LLC, an innovative science and technology company, today announced results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results